General

Kadokawa CEO Confirms Sony's Buyout Interest: 'No Decision Has Been Made'
Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System
FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease
Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System
FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease
Delta Will Serve Shake Shack Burgers As Airline Continues Catering To First-Class
Starfield Reaches 15 Million Players With Updates, New Content

General Recent News

Google's 'Unlawful Behavior' Stifles Market Entry For Rivals: DOJ Says Alphabet Must Sell Chrome To End Search Monopoly
Google has criticized these proposals as extreme, arguing they would harm U.S. consumers and businesses.
Indian Billionaire, One Of The World's Richest Men, Indicted For Alleged $250 Million Bribery Scheme
Indian billionaire and chair of the conglomerate Adani Group, Gautam Adani, was indicted in the U.S. Wednesday for an alleged scheme to pay hundreds of millions of dollars in bribes and concealing the scheme from American investors.
Hedge Funder Linked To Credit Suisse Collapse Gets 18 Year Prison Sentence For Fraud, Market Manipulation
Archegos Capital Management founder Bill Hwang was sentenced on Wednesday to 18 years in prison for fraud and market manipulation tied to the fund's dramatic collapse. 
Play PS5 Games Without A Console: PlayStation Portal Adds Cloud Streaming
PlayStation Portal now supports cloud streaming for PS Plus Premium members. Stream over 120 PS5 games in beta.
Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted
QuidelOrtho's secondary offering of 8.26 million shares is priced at $38.58, removing an investor overhang, according to William Blair's analysis.
Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate
Eli Lilly and Verge Genomics advance ALS drug development with validated targets and a Phase 1B study, part of their $694 million collaboration since 2021.
Inspire Medical's Strong 2025 Outlook And Upcoming Inspire V Launch Earns Analyst Upgrade
BofA upgrades Inspire Medical to Buy, setting a $255 price target. The company aims for $950 million in 2025 revenue, with a focus on new product launches and expansion.
Target Margins And Inventory Issues Raise Analyst Caution After Weak Q3 Performance
Target's weak Q3 results and lowered FY24 outlook raise concerns over margins, inventory, and digital growth, with analysts expressing caution.
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024.
Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs
Viking Therapeutics' Phase 2b results show VK2809's efficacy in treating NASH, with significant liver fat reductions, NASH resolution, and fibrosis improvement.
What's Going On With C3.ai Stock Wednesday?
C3.ai's stock is down despite announcing expanded partnerships with Capgemini.
'Trump-Elon Trade' Lifts Space Stocks Higher
Several pure-play space stocks, including RocketLab USA and Intuitive Machines, have rallied significantly following the presidential election. Here's why.
What's Going On With Lifeway Stock After Rejecting Revised Acquisition Offer From Danone?
Lifeway Foods shares fall after rejecting Danone's $27 per share acquisition offer, citing undervaluation and prioritizing growth.
What's Going On With GlobalFoundries Stock Today?
GlobalFoundries (GFS) stock drops 2.71% despite receiving up to $1.5B funding from the U.S. Department of Commerce for semiconductor expansion.
After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
Sage Therapeutics ends dalzanemdor development after Phase 2 trials for Huntington's and Alzheimer's fail to meet primary endpoints.

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved